
    
      it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed
      type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided
      to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index(
      fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and
      recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg
      daily, 6 month). during the study, the above mentioned parameters will also be recorded 3
      month intervals. Meanwhile, any side effects would be pay attention.
    
  